FLEMINGTON, N.J., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused primarily on the development of oncology therapeutics, today announced that it has appointed Alexander Zukiwski, M.D. to its Board of Directors. The Board of Directors also appointed Dr. Zukiwski as the Company's Chief Executive Officer. Dr. Zukiwski, who had served as the Company's Interim CEO since July 2014, will also continue in his role as Arno's Chief Medical Officer.
Dr. Arie Belldegrun, Chairman of the Board of Directors said, "On behalf of the Board, we would like to congratulate Dr. Zukiwski for his appointment as CEO and as a Director. His leadership, commitment and dedication to Arno since he joined the Company in 2011, including his tenure as interim CEO, made this decision an easy one for all of us. We have a great deal of confidence in Alex and his vision to move onapristone forward and to maximize the success of Arno for our shareholders."
Dr. Zukiwski added, "It is an honor to be named CEO and appointed to the Board of Arno. It remains my paramount goal, both as an executive and physician, to advance the clinical development of onapristone, which is currently being evaluated in a Phase I trial in women with progesterone receptor expressing tumors and a Phase I/II trial in men with advanced, castration-resistant prostate cancer, as well as plan for the continued development of our two additional compounds, AR-42 and AR-12. I look forward to working with the Board of Directors to achieve the objectives of the Company and further demonstrate the potential that our unique hormone therapy approach may have in treating cancer."
In addition to Dr. Zukiwski's appointment, the Company announced that Randy Thurman has resigned from the Company's Board of Directors.
"The Board would also like to thank Randy for the guidance and leadership he provided Arno while a director of the Company," commented Dr. Belldegrun. "We all wish him continued success in his many other endeavors."
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer and other life threatening diseases. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical and preclinical development as product candidates to treat hematologic malignancies and solid tumors. For more information about the company, please visit www.arnothera.com.
This press release contains forward-looking statements that involve substantial risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements regarding the timing, progress and anticipated results of the clinical development of onapristone, statements regarding the potential of onapristone as a treatment for prostate and other cancers, as well as Arno's strategy, future operations, outlook, milestones, future financial position, future financial results, plans and objectives. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make. Such factors include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of onapristone or any of our other product candidates, our ability to successfully develop a diagnostic to identify APR tumors, our ability to finance the development of our product candidates, regulatory risks, and our reliance on third party researchers and other collaborators. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2013 and its Quarterly Report for the quarter ended September 30, 2014. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
CONTACT: The Ruth Group Lee Roth (investors) email@example.com (646) 536-7012 Kirsten Thomas (media) firstname.lastname@example.org (646) 536-7014 Arno Therapeutics Lawrence Kenyon email@example.com (862) 703-7171
Source:Arno Therapeutics Inc.